- Home
- RPAY vs AVXL Comparison
RPAY vs AVXL Comparison
Compare RPAY & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- AVXL
- Stock Information
- Founded
- RPAY 2006
- AVXL 2004
- Country
- RPAY United States
- AVXL United States
- Employees
- RPAY N/A
- AVXL N/A
- Industry
- RPAY Business Services
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPAY Consumer Discretionary
- AVXL Health Care
- Exchange
- RPAY Nasdaq
- AVXL Nasdaq
- Market Cap
- RPAY 387.2M
- AVXL 761.3M
- IPO Year
- RPAY N/A
- AVXL N/A
- Fundamental
- Price
- RPAY $4.00
- AVXL $8.41
- Analyst Decision
- RPAY Buy
- AVXL Strong Buy
- Analyst Count
- RPAY 8
- AVXL 2
- Target Price
- RPAY $9.69
- AVXL $44.00
- AVG Volume (30 Days)
- RPAY 1.8M
- AVXL 693.1K
- Earning Date
- RPAY 05-12-2025
- AVXL 05-13-2025
- Dividend Yield
- RPAY N/A
- AVXL N/A
- EPS Growth
- RPAY N/A
- AVXL N/A
- EPS
- RPAY N/A
- AVXL N/A
- Revenue
- RPAY $313,042,000.00
- AVXL N/A
- Revenue This Year
- RPAY $0.54
- AVXL N/A
- Revenue Next Year
- RPAY $7.52
- AVXL N/A
- P/E Ratio
- RPAY N/A
- AVXL N/A
- Revenue Growth
- RPAY 5.53
- AVXL N/A
- 52 Week Low
- RPAY $3.59
- AVXL $3.51
- 52 Week High
- RPAY $11.27
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- RPAY 38.14
- AVXL 44.88
- Support Level
- RPAY $3.59
- AVXL $8.20
- Resistance Level
- RPAY $4.57
- AVXL $8.81
- Average True Range (ATR)
- RPAY 0.21
- AVXL 0.39
- MACD
- RPAY 0.04
- AVXL -0.10
- Stochastic Oscillator
- RPAY 39.80
- AVXL 26.25
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.